These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 17295666

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 25. The Remission Clinic approach to halt the progression of kidney disease.
    Remission Clinic Task Force, Clinical Research Center "Aldo e Cele Daccò".
    J Nephrol; 2011 Oct; 24(3):274-81. PubMed ID: 21534237
    [Abstract] [Full Text] [Related]

  • 26. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M.
    Rev Prat; 2004 Jun 15; 54(11):1167-74. PubMed ID: 15496022
    [Abstract] [Full Text] [Related]

  • 27. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA, Götz AK, Krüger B, Hösl M, Schmitz G, Riegger GA, Krämer BK.
    Eur J Med Res; 2005 Apr 20; 10(4):161-8. PubMed ID: 15946912
    [Abstract] [Full Text] [Related]

  • 28. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
    Diabet Med; 2007 May 20; 24(5):486-93. PubMed ID: 17367311
    [Abstract] [Full Text] [Related]

  • 29. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
    Palmer BF.
    Am J Med; 2008 Aug 20; 121(8 Suppl):S16-22. PubMed ID: 18638614
    [Abstract] [Full Text] [Related]

  • 30. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL, Craddock D, Edwards K.
    Pharmacotherapy; 2006 Sep 20; 26(9):1297-306. PubMed ID: 16945052
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.
    Komers R, Simkova R, Kazdova L, Ruzickova J, Pelikanova T.
    J Renin Angiotensin Aldosterone Syst; 2004 Mar 20; 5(1):33-8. PubMed ID: 15136972
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul 20; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 36. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N, Hashimoto N, Suzuki Y, Yagui K, Saito Y.
    Diabetes Res Clin Pract; 2006 May 20; 72(2):135-41. PubMed ID: 16290123
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S, Aurell M.
    J Am Soc Nephrol; 1990 Nov 20; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [Abstract] [Full Text] [Related]

  • 38. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S, Tomonari H, Ohtsuka Y, Ohkido I, Hosoya T.
    Nihon Jinzo Gakkai Shi; 2003 Nov 20; 45(4):367-71. PubMed ID: 12806973
    [Abstract] [Full Text] [Related]

  • 39. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
    Swislocki AL, Siegel D.
    Am J Manag Care; 2001 Mar 20; 7(3):283-95. PubMed ID: 11258145
    [Abstract] [Full Text] [Related]

  • 40. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
    Esnault V.
    Nephrol Ther; 2006 May 20; 2 Suppl 3():S193-6. PubMed ID: 17370850
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.